Target | Drug | NCT number (status) | Design | Primary end-point |
---|---|---|---|---|
JAK/STAT signalling pathway | Belumosudil | 03919799 (recruiting) | Phase II Randomized, Double-Blind, Placebo-controlled study | Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) at Week 24 |
04680975 (recruiting) | Phase II, Open label, Multicenter Study | CRISS at Week 24 | ||
Itacitinib [59] | 04789850 (Not yet recruiting) | Phase II, Randomized, Quadruple-Blind, Placebo-Controlled Study | Change in modified Rodnan skin score (mRSS) at 360Â days | |
B cells | Belimumab and rituximab combination therapy (75) | 03844061 (recruiting) | Phase II, Randomized, Double-Blind, Placebo-Controlled Study | Change in the American College of Rheumatology (ACR) CRISS at 12Â months and the proportion of participants who experience at least one Grade 3 or higher adverse event at or before 12 months |